Skip to main content

Table 1 Demographic and behavioral characteristics of PEPI-MDS participants by recent use of menopausal hormones

From: Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study

Characteristic

Quit hormones to join PEPI (n = 173)a

Did not quit hormones to join PEPI (n = 143)

Never used hormone therapy (n = 274)b

 

Mean (SD)

Frequency (%)

P c

Mean (SD)

Frequency (%)

P d

Mean (SD)

Frequency (%)

P e

Age, years

55.9 (4.1)

 

0.27

56.4 (4.8)

 

0.31

55.9 (4.2)

 

0.84

Years since menopause

5.6 (2.5)

 

0.26

6.0 (2.6)

 

0.15

5.5 (2.8)

 

0.86

Body mass index, kg/m2

25.2 (4.1)

 

0.003

26.7 (4.5)

 

0.66

26.5 (4.7)

 

0.002

Months since menopausal hormone usef

6.5 (12.0)

 

<0.001

47.8 (60.0)

 

N/A

N/A

 

N/A

Alcohol use, g/day

6.2 (9.9)

 

0.99

6.1 (12.1)

 

0.67

6.7 (14.1)

 

0.66

Percentage mammographic density

0.28 (0.18)

 

0.01

0.23 (0.17)

 

0.68

0.23 (0.18)

 

0.01

Total hip bone mineral density, g/cm2

0.866 (0.128)

 

0.82

0.863 (0.127)

 

0.71

0.858 (0.120)

 

0.51

Lumbar bone mineral density, g/cm2

0.997 (0.164)

 

0.01

0.952 (0.154)

 

0.54

0.962 (0.154)

 

0.02

Non-white, number (%)

 

13 (7.5)

0.007

 

25 (17.5)

0.10

 

32 (11.7)

0.15

Smoking

   Current

 

10 (5.8)

0.01

 

24 (16.1)

0.74

 

43 (15.7)

0.006

   Former

 

73 (42.2)

  

55 (38.5)

  

96 (35.0)

 

   Never

 

90 (52.0)

  

65 (45.5)

  

135 (49.3)

 

Physical activity level, number (%)g

   Low (score < 1.5)

 

47 (27.1)

0.04

 

58 (40.6)

0.31

 

91 (33.2)

0.40

   Medium (score = 1.5)

 

64 (37.0)

  

42 (29.4)

  

95 (34.7)

 

   High (score > 1.5)

 

62 (35.8)

  

43 (30.1)

  

88 (32.1)

 
  1. Of the 594 women who had adequate mammographic density measurements, 4 did not have complete information on other variables and are not included in the analyses. The table displays information regarding the remaining 590 women.
  2. aWomen who were using menopausal hormone therapy at the time of recruitment could join the trial if they stopped their privately prescribed hormone therapy at least 2 months before the first screening visit. A total of 317 participants answered the question regarding whether they quit menopausal hormone therapy to join PEPI.
  3. bThis column also includes women who did not remember whether they had used hormone therapy.
  4. cP value comparing the characteristic in the participants who quit hormones to join PEPI with the participants who did not quit hormones to join PEPI.
  5. dP value comparing the characteristic in the participants who did not quit hormones to join PEPI with the participants who never used hormone therapy.
  6. eP value comparing the characteristic in the participants who never used hormone therapy with the participants who quit hormones to join PEPI.
  7. fNumber of months since menopausal hormone therapy use in women who had used hormones previously. In the overall sample, the mean duration since last use of hormone therapy was 4.1 months (range 3.1 to 5.1 months).
  8. gLeisure and home physical activity self-rated by participants: inactive (1), light (2), moderate (3).
  9. PEPI, Postmenopausal Estrogen/Progestin Interventions Study; PEPI-MDS, PEPI Mammographic Density Study.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us